Content Links:

Program Overview
Target Audience
Learning Objectives
Program Faculty
Physician Continuing Medical Education
Disclosure of Conflicts of Interest
Instructions for Partcipation and Credit
Disclosure of Unlabeled Use

Program Overview:

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017). This program consists of four components: (1) CME Internet Symposium: CROI 2017 Expert Review: an Internet symposium featuring an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (3) Rapid-Fire Review of CROI 2017: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data From CROI 2017: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The CME Internet Symposium: CROI 2017 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at CROI 2017. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2017 and it is not sanctioned by the organizers of CROI 2017. 

Back to Top

Target Audience: 

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top 

Learning Objectives: 

After completing this activity, the participant should be better able to:

  • Use data reported at CROI 2017 for counseling, testing and antiretroviral treatment to prevent HIV infection, especially in underserved communities
  • Use in a clinical setting findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at CROI 2017
  • Employ strategies based on studies and data presented at CROI 2017 for helping HIV-positive patients in medically underserved communities link to and stay in appropriate and effective HIV care
  • Discuss with patients and colleagues the studies and data on therapies for HIV/AIDS presented at CROI 2017 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: February 28, 2017

Expiration Date: February 28, 2018

Estimated time to complete the program: 2 hours

Back to Top


Program Faculty: 

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain  

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC

Paul Sax, MD, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois

Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Back to Top

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest: 

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Jose Arribas, MD

  • Consulting Fees: Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: ViiV, Janssen, Abbvie, BMS,Gilead, MSD

Richard Elion, MD

  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead, Merck, Janssen
Ian Frank, MD


  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GSK

Graeme Moyle, MD

  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: BMS, Gilead, Merck, Tobira/Allergen, Teva, Mylan

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbvie, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Abbot, Gilead, Merck
  • Contracted Research: Gilead

Paul Sax, MD

  • Consulting Fees: Abbvie, BMS, GSK/ViiV, Gilead, Janssen, Merck
  • Contracted Research: Gilead, BMS, GSK/ViiV

Renslow Sherer, MD

  • Consulting Fees: Gilead

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP have nothing to disclose.

Back to Top

Instructions for Particiaption and Credit

There are no fees for participating and receved CME credit for this activity.  During the period, February 28, 2017 through February 28, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12237.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top




This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.



Prepare to print

Share this page:

Get link code to this page                     

Back to Top